Long Islanders, doctors and industry experts weigh in on medicines like Ozempic and Wegovy — how they work, what they ...

Demand for weight-loss drugs, including GLP-1 medications such as Ozempic, Wegovy, and Mounjaro, has surged in the United States. In May 2024, a KFF Health Tracking Poll found that approximately 6 ...

Patients who stop using weight loss medications are likely to return to their baseline weight within two years, a new analysis finds. Newer medications, such as Mounjaro and Wegovy, exhibit both more ...

New research compared the effect of semaglutide vs. tirzepatide on weight loss over a 72 week period. Here's what the study ...

A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...

Overall, the study found, ceasing weight loss drugs is likely to yield ... and one pertaining to Mounjaro ("new" medications, approved for weight loss in 2021 and 2023, respectively).

Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant ...

The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...

Weight loss drugs are popular for helping patients quickly ... Qsymia was approved in 2021 for chronic weight management in adults. It was approved the following year for pediatric patients ...

Source: FactSet By The New York Times Sales of the weight-loss drug created boom times for Novo Nordisk. In 2023, the company’s extraordinary success prompted the Danish central bank to keep ...